Q32 Bio (QTTB) Gains from Sales and Divestitures (2022 - 2026)
Q32 Bio's quarterly Gains from Sales and Divestitures came in at $104737.0 in Q1 2026, down 1.87% quarter-over-quarter from $106737.0 in Q4 2025.
Q32 Bio has reported Gains from Sales and Divestitures for 4 years, with the latest figure at $104737.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Sales and Divestitures changed N/A year-over-year to $104737.0; the trailing twelve-month figure through Mar 2026 stood at $104737.0 (changed N/A YoY), and the FY2025 full-year result was $106737.0, changed N/A from the prior year.
- Gains from Sales and Divestitures for Q1 2026 stood at $104737.0, down from $106737.0 in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $373519.0 in Q4 2023, with the low at $87140.0 in Q1 2022.
- Average Gains from Sales and Divestitures over 4 years is $158787.0, with a median of $106737.0 recorded in 2025.
- Peak annual rise in Gains from Sales and Divestitures reached 249.44% in 2023, while the deepest fall reached 123.23% in 2023.
- Tracing QTTB's Gains from Sales and Divestitures over 4 years: stood at $106890.0 in 2022, then jumped by 249.44% to $373519.0 in 2023, then slumped by 71.42% to $106737.0 in 2025, then slipped by 1.87% to $104737.0 in 2026.
- The last three Gains from Sales and Divestitures figures came in at $104737.0 (Q1 2026), $106737.0 (Q4 2025), and $106737.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Q32 Bio | 162.94 Mn | 112.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 104,737.00 |
| Mar 31, 2026 | 104,737.00 |
| Dec 31, 2025 | 106,737.00 |
| Dec 31, 2025 | 106,737.00 |
| Sep 30, 2025 | 106,737.00 |
| Sep 30, 2025 | 106,737.00 |
| Dec 31, 2023 | 373,519.00 |
| Dec 31, 2023 | 373,519.00 |
| Sep 30, 2023 | 281,117.00 |
| Sep 30, 2023 | 281,117.00 |
| Jun 30, 2023 | 194,525.00 |
| Jun 30, 2023 | 194,525.00 |
| Mar 31, 2023 | 194,525.00 |
| Mar 31, 2023 | 194,525.00 |
| Dec 31, 2022 | 106,890.00 |
| Dec 31, 2022 | 106,890.00 |
| Sep 30, 2022 | 103,590.00 |
| Sep 30, 2022 | 103,590.00 |
| Jun 30, 2022 | 87,140.00 |
| Jun 30, 2022 | 87,140.00 |
| Mar 31, 2022 | 87,140.00 |
| Mar 31, 2022 | 87,140.00 |